SPEAKERS: Peter Huh, MD; Jenny Lim, MD and Paulina Sun, DO

PLANNER: Reena Bhargava, MD


  • To critically read a journal article and draw conclusions applicable to clinical practice regarding specific clinical problems by using a systematic and standardized approach
  • Utilizing the information obtained from the journal articles, the physician will demonstrate an analytical and investigative approach to patient care


1)  Nintedanib therapy has been proven beneficial in slowing progression of interstitial lung disease in all types of fibrosing lung disease. Flaherty, K. R., Wells, A. U., & Cottin, V. (2019). Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. The NEW ENGLAND JOURNAL OF MEDICINE, 381(1718). Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1908681

2)  Metoprolol use in COPD patients with no established indication for beta-blocker use including coexistence of cardiovascular use was proven to be of no clinical benefit with regards to prevention of COPD exacerbations but rather with evidence for a higher rate of   more severe exacerbations and hospitalizations than the COPD group which affects clinical practice.  Dransfield, M.T., Voelker H., Bhatt, S.P. et al (2019) Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med, doi: 10.1056/NEJMoa1908142

3)  E-cigarette use in patients have been correlated with outbreak of severe acute lung injury in adolescent to young adult population, prompting need for e-cigarette use screening. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin — preliminary report. N Engl J Med. September 2019:NEJMoa1911614. doi:10.1056/NEJMoa1911614

1 AMA PRA Category 1 Credit(s)™

The presenter & planning committee members for this activity have disclosed that they have no relevant relationships with commercial or industry organizations. The CME Department has reviewed their disclosure information for the planner(s) and/or committee/faculty for this program and they do not have relationships that present a relevant conflict of interest. Kaiser Permanente does not endorse any brand name products.

Kaiser Santa Clara is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The Kaiser Santa Clara designates this Live Activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Session date: 
Thursday, December 5, 2019 - 12:30pm to 1:30pm
MOB A1, 2 & 5
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance

Please login or register to take this course.
CME Office: